TraStuzumAb-Radiotherapy : Impact on the Cerebral Prevention

Interest of the Prophylactic Cerebral Radiotherapy in the Metastatic Breast Cancer Expressing HER2/NEU Treated by Trastuzumab

Evaluate the survival without metastasis in patients treated by Trastuzumab in association with other chemotherapies for a breast cancer expressing HER2-NEU.

Inclusion Criteria:

• Patients with breast cancer, expressing HER2-NEU (score +++ in ICH or ++ and amplification on FISH or CISH, SISH)
• Visceral metastasis, only or multiple
• First line metastasis treatment by Trastuzumab in association with chemotherapy
• Good general conditions: OMS=<2 or Karnofsky >=70%
• Age > 18 years and < 70 years
• Life expectancy >=3 mois
• No Trastuzumab since more of 6 months
• No cerebral metastasis (MRI)
• Efficacy contraception for women with genital capacities
• Consent signed by the patient

Exclusion Criteria

• Contraindication to IRM
• Psychiatric decease
• Prior cerebral radiotherapy,
• Geographical constraint, compromising the fallow of patients
• Infectious or other serious pathology, likely to stop the treatment
• Positive serology (HIV, hBC, hBS)
• Inclusion in an other clinical trial or in the 4 weeks before th inclusion
• Pregnant or breastfeeding women